Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...319320321322323324325326327328329...10671068»
  • ||||||||||  lenalidomide / Generic mfg., carfilzomib / Generic mfg.
    ADDITION OF CARFILZOMIB AS A THIRD AGENT IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA: SWITCHING FROM DOUBLET TO TRIPLET () -  May 13, 2022 - Abstract #EHA2022EHA_1972;    
    ISS was equally distributed, and all patients hadpreviously been treated with bortezomib and IMIDs, and were refractory to this agents...Carfilzomib was well tolerated, with grade 2 anemia in 39% (16/41) of patients,successfully managed by ESAs, without necessity of blood transfusions; 29%(12/41) grade 3-4 neutropenia (pegfilgrastim in primary prophylaxis wasgiven, no ospedalization was required, no septic shocks were observed); 34%(14/41) grade 2, 21% (9/41) grade 3 and 12% (5/41) grade 4 thrombocytopenia, without hemorrhagic events and transfusion-dependency...A cardiac monitoring was performed for all patients: hypertension (grade 2-3) in 34%(14/41) of patients; fatigue in 39% (16/31) of patients. Conclusion Carfilzomib-Lenalidomide-Dexamethasone has shown significant efficacy in a particularly severe setting of patients, relapsed and refractory to all available therapeutic resources, also lenalidomide, and it could be considered as a bridge to a second autologous or allogenic SCT.
  • ||||||||||  bortezomib / Generic mfg., dexamethasone / Generic mfg., bendamustine / Generic mfg.
    CHEMO OR CHEMO-FREE REGIMENS IN HEAVILY PRETREATED MULTIPLE MYELOMA? ROLE OF BENDAMUSTINE-BORTEZOMIB-DEXAMETHASONE (BVD) IN NOVEL AGENTS' ERA () -  May 13, 2022 - Abstract #EHA2022EHA_1971;    
    Median time to response was 1.3 months (r.1-3), median OS from diagnosis was 67.3 months (r.6-151), median OS from start of Bendamustine was 9.6 months (r.2-36). Conclusion The triplet Bendamustine-Bortezomib-Dexamethasone has shown significant efficacy in a particularly severe setting of patients, relapsed and refractory to all available therapeutic resources, and, in particular cases, it could be considered as a bridge to a second autologous or allogenic SCT,also after failure of novel agents.
  • ||||||||||  subasumstat (TAK-981) / Takeda
    SYNERGISTIC EFFICACY OF COMBINED SUMOYLATION AND PROTEASOME INHIBITION IN MULTIPLE MYELOMA () -  May 13, 2022 - Abstract #EHA2022EHA_1936;    
    Treatment regimens for MM include proteasome inhibitors (PIs) which are routinely combined with dexamethasone and chemotherapeutics or immunomodulatory drugs (IMiDs)...Induced resistance to the second generation PI carfilzomib (CFZ) enhanced SUMO pathway activity...Mechanistically, combinatorial treatment of subasumstat and CFZ enhanced genotoxic and proteotoxic stress and apoptosis. Conclusion Our findings reveal activated SUMOylation as a therapeutic target in MM and point to combined SUMO/proteasome inhibition as a novel and potent strategy for the treatment of patients with MM.
  • ||||||||||  Ninlaro (ixazomib) / Takeda
    CHARACTERIZATION OF MULTIPLE MYELOMA CELL LINES WITH ACQUIRED-RESISTANCE TO PROTEASOME INHIBITORS HIGHLIGHTS A LINK BETWEEN RESISTANCE AND METABOLIC DEREGULATION () -  May 13, 2022 - Abstract #EHA2022EHA_1926;    
    Finally, no significant cross-resistance was observed with other therapeutic agents (melphalan, dexamethasone or IMIDs), indicating that the observed drug resistance mechanisms are especially related to PIs...Conclusion Altogether, we developed acquired PIs resistant HMCLs that exhibit PSMB5 mutation as observed in patients, and we identified pathways linked to metabolism deregulation in these cell lines. These results make our PI-resistant models, an attractive preclinical model to test new therapeutic strategies to overcome PI resistance in MM.
  • ||||||||||  Olumiant (baricitinib) / Incyte, Eli Lilly, Xevudy (sotrovimab) / GSK, National Institutes of Health, Vir Biotech, National Institute of Allergy and Infectious Diseases
    VERY LOW MORTALITY IN DOUBLE VACCINATED IMMUNOCOMPROMISED HAEMATOLOGY PATIENTS INFECTED WITH SARS-COV-2. () -  May 13, 2022 - Abstract #EHA2022EHA_1623;    
    Conclusion Within our cohort of patients with haematological cancer diagnosed with COVID19 infection, the role of immunisations and presence of the Omicron strain within the community has resulted in a mortality rate of 4% which is lower than the rates observed in previous studies. Hospitalisation occurred in 48% of the patients, with risk factors of older age, being non- or partially vaccinated and likely non-Omicron strain of COVID19 identified.
  • ||||||||||  Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
    PEGFILGRASTIM IN THE SUPPORTIVE CARE OF HEAVILY PRETREATED MULTIPLE MYELOMA IN POMALIDOMIDE-BASED TREATMENT () -  May 13, 2022 - Abstract #EHA2022EHA_1567;    
    Conclusion Pegfilgrastim was well tolerated in all patients: main side effects in our patients were mild fever and bone pain (21.2%). In patients affected by heavily pretreated MM treated with pomalidomide-dexamethasone, pegfilgrastim seems to reduce the incidence of severe neutropenia and infections and may increase the possibility to maintain the scheduled time of treatment.
  • ||||||||||  Brukinsa (zanubrutinib) / BeiGene
    THE EFFICACY AND SAFETY OF ZANUBRUTINIB AND DEXAMETHASONE IN SYMPTOMATIC WALDENSTROM MACROGLOBULINNEMIA () -  May 13, 2022 - Abstract #EHA2022EHA_1552;    
    Treatment included chemotherapy(containing nitrogen mustard phenylbutyrate, fludarabine, cyclophosphamide), proteasome inhibitor regimens, rituximab regimens and immunomodulator regimens. Conclusion These results demonstrate that zanubrutinib and dexamethasone are quickly effective in the treatment of WM, with more deeper response and less toxicity.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    CLINICAL FEATURES AND OUTCOME OF PATIENTS WITH CASTLEMAN DISEASE: A SPANISH MULTICENTRIC STUDY OF 134 PATIENTS FROM GELTAMO () -  May 13, 2022 - Abstract #EHA2022EHA_1519;    
    Treatment of POEMS MCD was also diverse; 3 patients received lenalidomide plus dexamethasone, 2 polychemotherapy, 1 anti-IL-6 and 1 auto SCT (3 patients unrecorded)...Main c linical and biological characteristics of the CD subtypes Conclusion Castleman Disease subtypes have different characteristics and outcomes. First-line treatment is heterogeneous in MCD subtypes pointing a need for national guidelines.
  • ||||||||||  dexamethasone / Generic mfg., cladribine / Generic mfg.
    A CASE OF HAIRY CELL LEUKEMIA PRESENTED AS HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS () -  May 13, 2022 - Abstract #EHA2022EHA_1475;    
    HCL is usually associated with an indolent clinical picture and with a good prognosis, while HLH is mainly associated with aggressive lymphoma. This case illustrates a case of HCL with a difficult diagnosis and highlights the importance of considering HCL as a triggering factor for HLH
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    ACQUIRED WILLEBRAND SYNDROME REVEALING ASYMPTOMATIC MULTIPLE MYELOMA : A CASE REPORT () -  May 13, 2022 - Abstract #EHA2022EHA_1069;    
    The patient received 2 courses of chemotherapy combining bortezomib, thalidomide and dexamethasone...The patient was put on rituximab for his von Willebrand's disease according to the following protocol: 1g on Day 1, and on Day15...We recommend screening for AvWS in patients followed for onco-haematological pathologies when unexplained abnormal bleeding occurs. the treatment of the monoclonal gammapathy can allow the regression of the hemorrhagic manifestations in some cases.
  • ||||||||||  dexamethasone / Generic mfg., prednisone / Generic mfg.
    PREDICTIVE FACTORS OF DIFFERENTIATION SYNDROME IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA () -  May 13, 2022 - Abstract #EHA2022EHA_880;    
    Conclusion Differentiation syndrome is a significant complication secondary to the ground-breaking treatment of APL. It is necessary to accurately identify high risk patients in order to elaborate effective risk-adapted prophylaxis and treatment.
  • ||||||||||  REAL-WORLD ANALYSIS OF THE RISKS OF THROMBOTIC AND BLEEDING EVENTS IN PATIENTS RECEIVING PEGYLATED ASPARAGINASE FOR TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA () -  May 13, 2022 - Abstract #EHA2022EHA_625;    
    Aims We aimed to assess the risk of thrombotic and bleeding events in patients with ALL treated with PEG-Asp and compare the treatment modalities with either AT3 + fibrinogen repletion vs the addition of prophylactic anticoagulation (AC) with either subcutaneous heparin 5000 TID or subcutaneous lovenox 30-40mg/day...The rates of thromboses or bleeding events were not different when either prednisone or dexamethasone were included in the induction treatment regimen...In our study, there was both a statistically significant increase in the rate of any thrombotic event as well as a trend towards increased bleeding in patients receiving AT3/cryoprecipitate + prophylactic anticoagulation versus those receiving AT3/cryoprecipitate alone. More investigation into the relative thrombotic and bleeding risks associated with PEG-Asp is needed to determine optimal antithrombotic interventions in adult patients with ALL.
  • ||||||||||  Jakafi (ruxolitinib) / Novartis, Incyte, CHZ868 - Novartis, Memorial Sloan / Kettering Cancer Center
    IN VITRO AND IN VIVO EFFICACY OF A NOVEL KINASE INHIBITOR TARGETING JAK2 GENE REARRANGEMENTS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA () -  May 13, 2022 - Abstract #EHA2022EHA_592;    
    In combination with dexamethasone, a further decrease of viability was observed...Importantly, combination of BIBF1120 and CHZ868 showed a synergistic effect (-45%, at IC50)...Indeed, active caspase 3 increased after ruxolitinib and chloroquine (autophagy inhibitor) combination(+20% vs ruxolitinib alone, p<0.01)...Conclusion CHZ868 is a promising drugfor the treatment of JAK2 fusionsBCP-ALL. Further studies will include combination with standard chemotherapy drugs, by reducing the intensity and toxicity of chemotherapy.
  • ||||||||||  thapsigargin / University of Nottingham, Pirbright Institute, Mifeprex (mifepristone) / Danco Laboratories
    A CHEMOTRANSCRIPTOMIC SCREENING IDENTIFIES THE REVERSAL OF GLUCOCORTICOID RESISTANCE IN NOTCH1 MUTATED T-ALL () -  May 13, 2022 - Abstract #EHA2022EHA_588;    
    Consequently, the association of SI plus GC displayed a synergistic effect in multiple preclinical models, including steroid-resistant cell lines, primary leukemia cells, and PDX models. Conclusion These findings suggest that SERCA-Ca 2+ modulation mediates GC and steroid signaling and that innovative SI can pharmacologically modulate glucocorticoid resistance in T-ALL.
  • ||||||||||  Ninlaro (ixazomib) / Takeda
    Phase classification:  Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome (clinicaltrials.gov) -  May 13, 2022   
    P1,  N=21, Active, not recruiting, 
    Conclusion These findings suggest that SERCA-Ca 2+ modulation mediates GC and steroid signaling and that innovative SI can pharmacologically modulate glucocorticoid resistance in T-ALL. Phase classification: P2 --> P1
  • ||||||||||  Promacta (eltrombopag) / Novartis
    Loss of response after discontinuation of eltrombopag in a patient with immune thrombocytopenia secondary to COVID-19: another finding of "persistent COVID syndrome"? (ExCel Center, ICC Capital Suite Room 1) -  May 13, 2022 - Abstract #ISTH2022ISTH_2478;    
    On discharge they had severe IT associated with skin bleeding events, initially treated with oral prednisone mg/kg/day plus unspecific IVIg g/kg/day (no hematologic response in both cases) and dexamethasone 40 mg for 4 days plus unspecific IVIg g/kg/day every 15 days (3 cycles), without response. Second-line treatment was started with TPO analogues (oral eltrombopag 50 mg/day, with dose escalation to 75 mg/day), obtaining haematological response on day +7 of start and complete remission on day +21 of treatment.
  • ||||||||||  Promacta (eltrombopag) / Novartis, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    An Escalating Treatment Strategy for Children with Chronic Immune Thrombocytopenia (Exhibition) -  May 13, 2022 - Abstract #ISTH2022ISTH_195;    
    Overall response was achieved in 72.41% of patients in the group A vs 68.97% in the group B, and the complete response (CR) rate was 34.48% in the group A compared with 20.69% in the group B. There was no difference between two groups (p＞0.05). Conclusion(s): This study suggests that escalating treatment strategy can achieve the similar efficacy as TRAs.
  • ||||||||||  prednisolone / Generic mfg., cyclophosphamide / Generic mfg.
    Acquired haemophilia presenting in a 14-year-old girl (Exhibition) -  May 13, 2022 - Abstract #ISTH2022ISTH_171;    
    Past medical and family histories were negative. Prior to admission the girl was seen by several paediatricians, rheumatologists and orthopaedists.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Journal:  Secondary Infection Risk in Patients With Severe COVID-19 Pneumonia Treated With Tocilizumab. (Pubmed Central) -  May 12, 2022   
    Although the benefit of tocilizumab in reducing mortality is well-established and almost certainly outweighs secondary infection risks, we question if the "real-world" infection rates are much higher than those reported in trials or if the infection risk could be mitigated with dose reductions in tocilizumab without losing the mortality benefit. Further study into the infection risk, and risk-benefit analysis of dose adjustments, of tocilizumab in the critical care setting is warranted.